Petrich, A. M., Pro, B., Nelson, V., Winter, J. N., Stephens, D. M., Ma, S., . . . Takvorian, R. W. (2020). Ibrutinib Maintenance (I-M) Following Intensive Induction in Mantle Cell Lymphoma (MCL): Efficacy, Safety and Changes in Minimal Residual Disease. Blood, 136, 30-31. https://doi.org/10.1182/blood-2020-137695
Citace podle Chicago (17th ed.)Petrich, Adam M., et al. "Ibrutinib Maintenance (I-M) Following Intensive Induction in Mantle Cell Lymphoma (MCL): Efficacy, Safety and Changes in Minimal Residual Disease." Blood 136 (2020): 30-31. https://doi.org/10.1182/blood-2020-137695.
Citace podle MLA (9th ed.)Petrich, Adam M., et al. "Ibrutinib Maintenance (I-M) Following Intensive Induction in Mantle Cell Lymphoma (MCL): Efficacy, Safety and Changes in Minimal Residual Disease." Blood, vol. 136, 2020, pp. 30-31, https://doi.org/10.1182/blood-2020-137695.